Jacobio Pharma (1167.HK), a clinical-stage oncology company, announced on Sunday that it has received approval for its registrational phase III clinical trial of the combination therapy of its novel KRAS G12C inhibitor glecirasib and novel SHP2 inhibitor JAB-3312.
JAB-3312 is the first SHP2 inhibitor, entered into phase III study globally in combination with KRAS G12C inhibitor.
This approved study, a randomised active controlled phase III trial design conducted in China, is to assess the efficacy and safety of JAB-3312 along with glecirasib for first-line non-small cell lung cancer (NSLC) subjects with KRAS G12C mutations. The control arm is the current standard treatment for first-line NSLC, which is the combination therapy of PD-1 antibody and chemotherapy.
The firm commenced clinical trials of SHP2 inhibitors in 2018. The company's JAB-3312 and glecirasib are both oral formulations, and the combination therapy is also the first approved Phase III registration clinical trial for dual oral inhibitors in the first-line treatment of NSLC globally.
Quest Diagnostics acquires OhioHealth lab assets
Exelixis and Merck collaborate on clinical development of zanzalintinib
BD launches automated reagent kit to streamline single-cell discovery studies
Transgene's Phase II trial of TG4001 falls short of primary objective
SkylineDx reveals new data from the MERLIN_001 prospective US multi-centre trial
Turnstone Biologics announces strategic restructuring
Pfizer's TALZENNA plus XTANDI shows promise in prostate cancer treatment
GenesisCare UK selects RayStation for radiotherapy system upgrade
Boehringer Ingelheim and Circle Pharma collaborate on cancer treatment
Petauri launches medical communications platform Petauri Advance
Bayer and MOMA Therapeutics enter oncology collaboration
GBI Biomanufacturing agrees manufacturing collaboration with Allterum Therapeutics
MediLink enters clinical trial collaboration and supply agreement with Amgen